CorMedix (CRMD)
CorMedix Market Cap: 3.081M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
CRMD Market Cap Rankings
| Overall | 0th percentile | 4626 of 4649 |
| Sector | 0th percentile | 523 of 525 in Healthcare |
| Industry | 0th percentile | 163 of 164 in Biotechnology |
CRMD Market Cap Range, Past 5 Years
| Minimum | 3.081M | May 25 2012 |
| Maximum | 25.10M | Jun 2010 |
| Average | 13.57M |
About Market Capitalization
Market Capitalization (Market Cap) is a measurement of business value based on share price and number of shares outstanding. It generally represents the market's view of a company's stock value and is a determining factor in stock valuation.
For example, if a company has 1.5 million shares outstanding at a share price of $25, its market cap is $37.5 million (1.5 million x $25). Companies can be categorized based upon the size of their market capitalization.
There are five basic groups: mega-cap (market cap over $200B), large-cap ($10B–$200B), mid-cap ($2B–$10B), small-cap ($300M–$2B), and micro-cap ($50M-$300M). Market cap is not always an accurate indication of value because it does not account for debt and other factors.
Learn More
You may also be interested in these CRMD related companies
CRMD News
CorMedix Strengthens Management Team with Addition of Randy Milby as Chief Operating Officer
May 03, 8:00AM Business Wire
May 03, 8:00AM Business Wire
Top Winners last Monday, March 5, 2012: #AMEX: $GV,$CRMD,$CUO,$RWC,$EGT #MarkeScope #StockMarket #Economy #Investment #Stocks
about 83 days ago by MarkeScope
about 83 days ago by MarkeScope
CorMedix (CRMD) Announces Funding Through NJEDA; Progressing Toward CE Approval of Neutrolin
Dec 30, 7:58AM Street Insider
Dec 30, 7:58AM Street Insider
CorMedix Appoints Pharmaceutical Veteran, Matthew Duffy to Board of Directors
Nov 28, 7:15AM Business Wire
Nov 28, 7:15AM Business Wire
CorMedix to Present at the Rodman & Renshaw Annual Global Investment Conference
Sep 07, 7:30AM Business Wire
Sep 07, 7:30AM Business Wire
CorMedix (CRMD) Amends Milestone Date, Payment With Shiva in CRMD001 Development
Sep 06, 7:45AM Street Insider
Sep 06, 7:45AM Street Insider
CorMedix Announces Amended Agreement for CRMD001 (A Proprietary Formulation of Deferiprone)
Sep 06, 7:30AM Business Wire
Sep 06, 7:30AM Business Wire
($CRMD) CORMEDIX SUBMITS DESIGN DOSSIER FOR NEUTROLIN® (CRMD003) TO START EUROPEAN APPROVAL PROCESS http://stk.ly/qgl778
about 326 days ago by CorMedix
about 326 days ago by CorMedix
CorMedix provides Regulatory update on Neutrolin ($CRMD) #FDA http://stk.ly/lrMZ7Y
about 340 days ago by CorMedix
about 340 days ago by CorMedix
CorMedix $CRMD receives SPA from FDA for Deferiprone Phase 3 trial http://stk.ly/iL48Vp
about 342 days ago by CorMedix
about 342 days ago by CorMedix
Trading Alert: CorMedix ($CRMD) Stock Chart on Breakout Watch
http://stk.ly/kkhNdA
about 389 days ago by CorMedix
about 389 days ago by CorMedix
($CRMD) TooNiceStocks.com Initiates Coverage on CorMedixhttp://stk.ly/hp38n9
about 425 days ago by CorMedix
about 425 days ago by CorMedix
($CRMD)http://www.proactivenewsroom.com/Blog/bid/61746/Cormedix-CRMD-Therapies-Address-Topic-in-Wall-Street-Journal
about 426 days ago by CorMedix
about 426 days ago by CorMedix
CorMedix ($CRMD) http://www.proactivenewsroom.com/Blog/bid/61243/CorMedix-CRMD-Technical-Chart-Continues-Bullish-Trend
about 426 days ago by CorMedix
about 426 days ago by CorMedix
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| CRMD | 0.27 | -0.01 | -3.50% | 3.081M |
| CRM | 147.00 | +0.79 | +0.54% | 20.14B |
| CRL | 33.56 | +0.21 | +0.63% | 1.641B |
| CPA | 83.85 | +0.62 | +0.74% | 3.713B |
| CP | 74.95 | -0.57 | -0.75% | 12.81B |
| COY | 7.40 | -0.04 | -0.54% | |
| COWN | 2.39 | +0.00 | +0.00% | |
| COVR | 1.54 | +0.00 | +0.00% | 39.42M |
| COV | 53.32 | -0.14 | -0.26% | 25.77B |
| COT | 7.55 | +0.11 | +1.48% | 718.00M |
